A simplified intravenous glucose loading protocol for fluorine-18 fluorodeoxyglucose cardiac single-photon emission tomography

European Journal of Nuclear Medicine

Volumn 24, Issue 10, 1997, Pages 1291-1297

  Martin, William H ^a   Jones, Robert C ^a   Delbeke, Dominique ^a   Sandler, Martin P ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fluorodeoxyglucose; Myocardial ischemia; Myocardial viability; Single photon emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; POTASSIUM;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; FEMALE; HEART MUSCLE ISCHEMIA; HEART SCINTISCANNING; HUMAN; IMAGE QUALITY; INTRAVENOUS DRUG ADMINISTRATION; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CASE-CONTROL STUDIES; EXERCISE TEST; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLUCOSE; GLUCOSE TOLERANCE TEST; HEART; HUMANS; INSULIN; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; POTASSIUM; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0030725545     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050154     Document Type: Article

References (43)

1. Altehoefer C, vom Dahl J, Biedermann M, et al. Significance of defect severity in technetium-99m-MIBI SPECT at rest to assess myocardial viability: comparison with fluorine-18-FDG PET. J Nucl Med 1994; 35: 569-574.
2. Dilsizian V, Rocco T, Freedman N. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 1990; 323: 141-146.
3. Tamaki N, Ohtani H, Yamashita K, et al. Metabolic activity in areas of new fill-in after thallium-201 reinjection: comparison with positron emission tomography using fluorine-18-deoxyglucose. J Nucl Med 1991; 32: 673-678.
4. Knuuti MJ, Saraste M, Nuutila P, et al. Myocardial viability: fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization. Am Heart J 1994; 127: 785-796.
5. Lucignani G, Paolini G, Landoni C, et al. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med 1992; 19: 874-881.
6. Tamaki N, Yonekura Y, Konishi J. Myocardial FDG PET studies with the fasting, oral glucose-loading or insulin clamp methods. J Nucl Med 1992; 33: 1263-1268.
7. Knuuti MJ, Nuutila P, Ruotasalainen U, et al. The value of quantitative analysis of glucose utilization in detection of myocardial viability by PET. J Nucl Med 1993; 34: 2068-2075.
8. Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314: 884-888.
9. Eitzman D, Al-Aouar Z, Kanter HL, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992; 20: 559-565.
10. DiCarli M, Davidson M, Little R, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994; 73: 527-533.
11. DiCarli M, Asgarzadie F, Schelbert H, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischmic cardiomyopathy. Circulation 1995; 92: 3436-3444.
12. Maddahi J, Schelbert H, Brunken R, DiCarli M. Role of thallium-201 and PET imaging in evaluation of myocardial viability and management of patients with coronary artery disease and left ventricular dysfunction. J Nucl Med 1994; 35: 707-715.
13. Burt RA, Perkins OW, Oppenheim BE, et al. Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPFCT for detection of myocardial viability. J Nucl Med 1995; 36: 176-179.
14. Martin WH, Delbeke D, Patton JA, et al. FDG-SPECT: correlation with FDG-PET. J Nucl Med 1995; 36: 988-995.
15. Sandler MP, Videlefsky S, Delbeke D, et al. Evaluation of myocardial ischemia using a rest metabolism/stress perfusion protocol with fluorine-18 deoxyglucose/technetium-99m MIBI and dual-isotope simultaneous-acquisition single-photon emission computed tomography. J Am Coll Cardiol 1995; 26: 870-878.
16. Delbeke D, Videlefsky S, Patton JA, et al. Rest myocardial perfusion/metabolism imaging using simultaneous dual-isotope acquisition SPECT with technetium-99m-MIBI/fluorine-18-FDG. J Nucl Med 1995; 36; 2110-2119.
17. Bax JJ, Cornel JH, Visser FC, van Lingen A, Fioretti PM. FDG SPECT versus stress-reinjection thallium SPECT to predict recovery of function after by-pass surgery. J Nucl Med 1996; 37 Suppl: 176P.
18. Bax JJ, Visser FC, Blanksma PK, et al. Comparison of myocardial uptake of fluorine-18-fluorodeoxyglucose imaged with PET and SPECT in dyssynergic myocardium. J Nucl Med 1996; 37: 1631-1636.
19. Wisneski JA, Gertz EW, Neese RA, Gruenke ED, Morris DL, Craig JC. Metabolic fate of extracted glucose in normal human myocardium. J Clin Invest 1985; 76: 1819-1827.
20. Berry JJ, Baker JA, Pieper KS, Hanson MW, Hoffman JM, Coleman RE. The effect of metabolic milieu on cardiac PET imaging using fluorine-18-deoxyglucose and nitrogen-13-ammonia in normal volunteers. J Nucl Med 1991; 32: 1518-1525.
21. Hicks RJ, Herman WH, Kalff V, et al. Quantitative evaluation of regional substrate metabolism in the human heart by positron emission tomography. J Am Coll Cardiol 1991; 18: 101-111.
22. Gropler RJ, Siegel BA, Lee KJ, et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med 1990; 31: 1749-1756.
23. Choi Y, Brunken RC, Hawking RA, et al. Factors affecting myocardial 1-[F-18]fluoro-2-deoxy-D-glucose uptake in positron emission tomography studies of normal humans. Eur J Nucl Med 1993; 20: 308-318.
24. 18F-labeled fluorodeoxyglucose and N-13 ammonia. Circulation 1983; 67: 766-778.
25. Henrich MM, Vester E, Jülicher F, et al. Myocardial glucose metabolism in patients with a coronary artery occlusion: a FDG-PET study in the fasted state and after glucose load [abstract]. J Nucl Med 1991; 32: 909.
26. Lewis P, Nunan T, Dynes A, Maisey M. The use of low-dose intravenous insulin in clinical myocardial F-18 FDG PET scanning. Clin Nucl Med 1996; 21: 15-18.
27. vom Dahl J, Herman WH, Hicks RJ, et al. Myocardial glucose uptake in patients with insulin-dependent diabetes mellitus assessed quantitatively by dynamic positron emission tomography. Circulation 1993; 88: 395-404.
28. Knuuti MJ, Nuutila P, Ruotsalainen U, et al. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J Nucl Med 1992; 33: 1255-1262.
29. Bax JJ, Visser FC, van Lingen A, et al. Image quality of cardiac FDG studies in diabetics using hyperinsulinemic glucose clamping. J Nucl Med 1995; 36: 36P-37P.
30. Ohtake T, Yokoyama I, Watanabe T, et al. Myocardial glucose metabolism in noninsulin-dependent diabetes mellitus patients evaluated by FDG-PET. J Nucl Med 1995; 36: 456-463.
31. Schelbert HR. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J Nucl Med 1992; 33: 1263-1266.
32. Schelbert HR. Metabolic imaging to assess myocardial viability. J Nucl Med 1994; 35 Suppl; 8S-14S.
33. Harris MI, Hadden WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in the US population aged 20-74 years. Diabetes 1987; 36: 523-534.
34. Bennett PH. Definition, diagnosis, and classification of diabetes mellitus and impaired glucose tolerance. In: Kahn CR, Weir GC, eds. Joslin's diabetes mellitus. 13th edn. Malvern, Pa.: Lea & Febiger; 1994: 193-200.
35. vom Dahl J, Hicks R, Lee K, Eitzman D, Alaouar Z, Schwaiger M. Positron emission tomography myocardial viability studies in patients with diabetes mellitus. J Am Coll Cardiol 1991; 17: 121A.
36. Prellwitz J, Vasta M, Sunderland J, Shiue C-Y, Gupta N, Frick M. Investigation of factors influencing FDG myocardial image quality. J Nucl Med 1991; 32: 1039.
37. Nuutila P, Koivisto VA, Knuuti J, et al. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest 1992; 89: 1767-1774.
38. Black HR. The coronary artery disease paradox: the role of hyperinsulinemia and insulin resistance and implications for therapy. J Cardiovasc Pharmacol 1990; 15 Suppl: S26-S38.
39. Rogers WJ, Russell RO, McDaniel HG, Rackley CE. Acute effects of glucose-insulin-potassium infusion on myocardial substrates, coronary blood flow and oxygen consumption in man. Am J Cardiol 1977; 40: 421-428.
40. Knuuti MJ, Yki-Jarvinen H, Voipio-Pulkki L-M, et al. Enhancement of myocardial [fluorine-18] fluorodeoxyglucose uptake by a nicotinic acid derivative. J Nucl Med 1994; 35: 989-998.
41. Stone CK, Holden JE, Stanley W, Perlman SB. Effect of nicotinic acid on exogenous myocardial glucose utilization. J Nucl Med 1995; 36: 996-1002.
42. Miyauchi T, Wahl RL. Regional 2-[18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung. Eur J Nucl Med 1996; 23: 517-523.
43. Nuutila P, Knuuti J, Ruotsalainen U, et al. Insulin resistance is localized to skeletal but not heart muscle in type 1 diabetes. Am J Physiol 1993; 264: E756-E762.